Certainly not simple, that's why AVXL failed in combo with another Sig-1 binder donepezil. Failed PR and the only US granted patent AVXL has for 273 for AD that I can see. https://www.anavex.com/anavex-reports-predicted-clinical-effect-for-anavex-2-73-in-computer-simulation-model-of-alzheimers-disease/ Then in 2016 realized the opposite apparently is in zero clinical trials due to that failed theory.
Market Data 
Markets 
AI
